These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38233673)

  • 1. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy.
    Wu D; Chen W
    Heart Fail Rev; 2024 Mar; 29(2):511-521. PubMed ID: 38233673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
    Nuvolone M; Girelli M; Merlini G
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM; Zhang K; Lenihan DJ; Witteles R
    Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
    Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
    Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
    Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
    Ruberg FL; Grogan M; Hanna M; Kelly JW; Maurer MS
    J Am Coll Cardiol; 2019 Jun; 73(22):2872-2891. PubMed ID: 31171094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy.
    Sha Q; Zhang Y; Wang M; Sun J; Zhang Y; Zhang X; Wang N; Liu Y; Liu Y
    ESC Heart Fail; 2024 Feb; 11(1):112-125. PubMed ID: 37827496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.